OBJECTIVE： To observe clinical efficacy and safety of valsartan combined with hydrochlorothiazide in the treatment of chronic renal disease complicated with hypertension. METHODS： A total of 156 chronic kidney disease patients with renal hypertensive were randomly divided into control group and observation group with 78 cases in each group. Control group was given hydrochlorothiazide tablets 25 mg orally，once a day. Observation group was additionally given valsartan capsule 80 mg orally，once a day， on the basis of control group. Treatment course of 2 groups lasted for 4 weeks. Clinical efficacies of 2 groups were observed and compared， and the levels of SBP， DBP， GFR， 24 h urine protein quantification， Scr and BUN were observed before and after treatment. The occurrence of ADR was recorded. RESULTS： After treatment， total response rate of observation group was significantly higher than that of control group， with statistical significance （85.90％ vs. 64.10％，P＜0.05）. Before treatment， there was no statistical significance in SBP， DBP， GFR， 24 h urine protein quantification， Scr and BUN between 2 groups （P＞0.05）. After treatment， SBP，DBP，24 h urine protein quantification，Scr and BUN of 2 groups were significantly lower than before treatment，the observation group was significantly lower than the control group， GFR was significantly higher than before treatment， the observation group was significantly higher than that of control group， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS： Valsartan combined with hydrochlorothiazide show good therapeutic efficacy for chronic renal disease complicated with hypertension， and can significantly improve blood pressure and renal function with good safety.